Sunrise Technologies set to reject tender offer
This article was originally published in Clinica
Sunrise Technologies is urging its shareholders to reject an unsolicited tender offer by Growth Capital Corporation for up to 2.3 million shares at $12.50 per share. Shares in the company currently stand at $12.25, compared with a year-high of $20.37 and a year-low of $2.75. Sunrise has around 46 million shares outstanding.
You may also be interested in...
An upturn in M&A activity across the whole healthcare sector is expected in 2021, with the COVID-19 pandemic and the associated development of a vaccine shining a light on the sector, says a recent survey by Jefferies.
Australian patients with phototoxicity due to the rare condition EPP will now have their first treatment option – provided the drug's developer, Clinuvel, secures reimbursement under the Pharmaceutical Benefits Scheme.
Roche has partnered with Regeneron and Atea, but the company continues to leverage its long legacy in infectious diseases to identify good treatment options for the novel coronavirus.